Quick Answer
Viking Therapeutics, Inc. reported Cash and Equivalents of $165.81 million for fiscal year 2025.
Viking Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $165.81M | +521.6% |
| 2024 | $26.68M | -51.9% |
| 2023 | $55.52M | +51.6% |
| 2022 | $36.63M | +38.9% |
| 2021 | $26.37M | -9.4% |
| 2020 | $29.12M | +247.6% |
| 2019 | $8.38M | -66.2% |
| 2018 | $24.78M | +175.7% |
| 2017 | $8.99M | +192.2% |
| 2016 | $3.08M | +300.2% |
| 2015 | $768.5K | +1.7% |
| 2014 | $755.9K | +320.8% |
| 2013 | $179.6K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $100.38M | +99.4% | +196.3% |
| June 30, 2025 | $33.88M | -22.9% | -10.7% |
| March 31, 2025 | $37.94M | -80.6% | +42.2% |
| December 31, 2024 | $26.68M | -51.9% | -47.0% |
| September 30, 2024 | $50.35M | +35.4% | +14.6% |
| June 30, 2024 | $43.91M | -36.8% | -77.5% |
| March 31, 2024 | $195.58M | +965.1% | +252.3% |
| December 31, 2023 | $55.52M | +51.6% | +49.3% |
- Viking Therapeutics, Inc. showed an increase of +521.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Viking Therapeutics, Inc.’s cash and equivalents has grown by 92212.1% (from $179.6 thousand to $165.81 million).
- The most recent figure is from Viking Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: